PW Medtech Group Ltd
PW Medtech Group Ltd is a medical equipment and supplies company that generates revenue primarily through the production and distribution of healthcare products.
Business. PW Medtech Group Ltd (1358.HK) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic presence are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PW Medtech Group Ltd (1358.HK) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic presence are not disclosed in the available data.
PW Medtech Group Ltd maintains a strong liquidity position, with cash and equivalents amounting to CNY 1.8 billion, representing 34.4% of total assets. The company's liquidity FPT (free cash flow to total debt) is robust, supported by a current ratio of 10.89 and a low debt-to-equity ratio of 0.01. This indicates minimal leverage and strong short-term financial flexibility.
Profitability metrics show a return on equity (ROE) of 2.39% and a return on assets (ROA) of 1.8%, both below the industry median for medical equipment and supplies firms. Gross profit margin stands at 49.4%, while operating margin is 14.8%, suggesting moderate efficiency in converting revenue to profit. These figures indicate room for improvement in cost management and pricing power.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory shifts. The absence of segment or geographic breakdown in the financial snapshot limits visibility into potential growth or risk areas.
PW Medtech Group Ltd's growth trajectory is modest, with no disclosed revenue growth rates or forward-looking guidance. The company's current FY revenue is CNY 823.5 million, and no numeric deltas for next FY are available. Analyst estimates for the last actual revenue were CNY 362.2 million, significantly lower than the reported figure, suggesting potential volatility or seasonal factors.
Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce financial distress risk. However, the absence of disclosed dilution sources or recent equity issuance does not rule out future capital-raising needs, particularly if growth initiatives require funding.
Recent events include the latest financial filing (market data), which provides the most recent revenue and profit figures. No recent earnings call transcripts or regulatory filings are available in the provided data, limiting insight into management commentary or strategic direction.
- Strong liquidity and low leverage support financial stability.
- ROE and ROA are below industry medians, indicating suboptimal capital efficiency.
- Revenue concentration in a single segment and lack of geographic diversification increase operational risk.
- No immediate dilution or liquidity risks are flagged, but growth initiatives may require future capital.
- Analyst estimates for revenue were significantly lower than actuals, suggesting potential volatility or reporting inconsistencies.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- PW Medtech Group Ltd Market data — financials · 2026-05-26
- PW Medtech Group Ltd Market data — analyst estimates · 2026-05-26